A Win For Ocugen, Inc.

Ocugen, Inc. (OCGN:NASDAQ) rocketted at $4.23, representing a gain of 22.3%. On Fri, Feb 18, 2022, OCGN:NASDAQ hit a New 2-Week Low of $3.46. The stock appeared on our News Catalysts scanner on Tue, Feb 22, 2022 at 05:29 PM in the 'PUBLIC OFFERING' category. From Mon, Feb 07, 2022, the stock recorded 22.22% Up Days and 30.00% Green Days

The stock spiked on Wed, Nov 03, 2021 at $17.65 with a volume of 214M+.

About Ocugen, Inc. (OCGN:NASDAQ)

Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).